Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Human Molecular Genetics

• Publication date

  2010-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/hmg/ddp548PMID 19995790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A restricted spectrum of NRAS mutations causes Noonan syndrome

  2010cited by this paper
• A BAR domain-mediated autoinhibitory mechanism for RhoGAPs of the GRAF family.

  2009cited by this paper
• Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome

  2009cited by this paper
• Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation

  2008cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders

  2008cited by this paper
• Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction

  2008cited by this paper
• Clinical and molecular aspects of RAS related disorders

  2008cited by this paper
• Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II

  2008cited by this paper
• Costello syndrome associated with novel germline HRAS mutations: An attenuated phenotype?

  2008cited by this paper
• Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Integrating signals from RTKs to ERK/MAPK

  2007cited by this paper
• COMBINE analysis of the specificity of binding of Ras proteins to their effectors

  2007cited by this paper
• Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome

  2007cited by this paper
• Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation

  2007cited by this paper
• Ras oncogenes and their downstream targets.

  2007cited by this paper
• HRAS and the Costello syndrome

  2007cited by this paper
• HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation

  2006cited by this paper
• Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.

  2006cited by this paper
• Stops along the RAS pathway in human genetic disease

  2006cited by this paper
• Mutations of the mitochondrial holocytochrome c-type synthase in X-linked dominant microphthalmia with linear skin defects syndrome.

  2006cited by this paper
• Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy

  2005cited by this paper
• Fluorescence approaches for monitoring interactions of Rho GTPases with nucleotides, regulators, and effectors.

  2005cited by this paper
• Guanine nucleotide exchange factors operate by a simple allosteric competitive mechanism.

  2005cited by this paper
• Germline mutations in HRAS proto-oncogene cause Costello syndrome

  2005cited by this paper
• Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases

  2005cited by this paper
• GTPase activating proteins: structural and functional insights 18 years after discovery

  2005cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation

  2004cited by this paper
• Costello syndrome: An overview

  2003cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Ras-effector interactions: after one decade.

  2003cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Fluorescence methods in the study of small GTP-binding proteins.

  2002cited by this paper
• The Guanine Nucleotide-Binding Switch in Three Dimensions

  2001cited by this paper
• Guanosine triphosphatase stimulation of oncogenic Ras mutants.

  1999cited by this paper
• The structural basis of the activation of Ras by Sos

  1998cited by this paper
• Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras

  1997cited by this paper
• Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy.

  1997cited by this paper
• Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras.

  1997cited by this paper
• The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

  1997cited by this paper
• Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS

  1996cited by this paper
• Multiple Ras functions can contribute to mammalian cell transformation.

  1995cited by this paper
• Phosphatidylinositol-3-OH kinase direct target of Ras

  1994cited by this paper
• Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules.

  1994cited by this paper
• Structural requirements for the interaction of p21ras with GAP, exchange factors, and its biological effector target.

  1993cited by this paper
• Kinetics of interaction between normal and proline 12 Ras and the GTPase-activating proteins, p120-GAP and neurofibromin. The significance of the intrinsic GTPase rate in determining the transforming ability of ras.

  1993cited by this paper
• Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction

  1993cited by this paper
• Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras

  1991cited by this paper
• A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction.

  1991cited by this paper
• Differential regulation of rasGAP and neurofibromatosis gene product activities

  1991cited by this paper
• Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP

  1991cited by this paper
• A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction.

  1991cited by this paper
• p21 with a phenylalanine 28----leucine mutation reacts normally with the GTPase activating protein GAP but nevertheless has transforming properties.

  1991cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Altered guanine nucleotide binding and H-ras transforming and differentiating activities

  1988cited by this paper
• Purification of ras GTPase activating protein from bovine brain.

  1988cited by this paper
• Isolation of ras GTP-binding mutants using an in situ colony-binding assay.

  1986cited by this paper
• The oncogenic activation of human p21ras by a novel mechanism.

  1986cited by this paper
• rasH mutants deficient in GTP binding

  1986cited by this paper

• The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

  2025cites this paper
• Dermatological manifestations in Costello syndrome: A prospective multicentric study of 31 HRAS‐positive variant patients

  2024cites this paper
• Multiplexed imaging for probing RAS-RAF interactions in living cells.

  2023cites this paper
• Twins with psychiatric features and a nonsense HRAS variant affecting transcript processing

  2023cites this paper
• Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways

  2022cites this paper
• Induced pluripotent stem cells for modeling Noonan, Noonan Syndrome with Multiple Lentigines, and Costello Syndromes

  2022cites this paper
• Multidisciplinary Management of Costello Syndrome: Current Perspectives

  2022cites this paper
• Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome

  2021cites this paper
• Synthetic dysmobility screen unveils an integrated STK40-YAP-MAPK system driving cell migration

  2021cites this paper
• The novel duplication HRAS c.186_206dup p.(Glu62_Arg68dup): clinical and functional aspects

  2020cites this paper
• Senescence in RASopathies, a possible novel contributor to a complex pathophenoype.

  2020influential citation
• New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.

  2019cites this paper
• RASopathy-associated Cardiomyopathy

  2019cites this paper
• Kouskou, Marianna and Thomson, David M. and Brett, Ros R. and Wheeler, Lee and Tate, Rothwelle J. and Pratt, Judith A. and Chamberlain, Luke H. (2018) Disruption of the Zdhhc9 intellectual disability gene leads to behavioural abnormalities in a mouse

  2019cites this paper
• Etude des anomalies du métabolisme énergétique associées au syndrome de Noonan

  2019cites this paper
• The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.

  2018cites this paper
• Disruption of the Zdhhc9 intellectual disability gene leads to behavioural abnormalities in a mouse model

  2018cites this paper
• C. elegans as a model to identify and functionally characterize novel genes causing RASopathies and other developmental diseases

  2017cites this paper
• Genotype and phenotype spectrum of NRAS germline variants

  2017cites this paper
• Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics

  2017cites this paper
• Retinal dystrophy in two boys with Costello syndrome due to the HRAS p.Gly13Cys mutation

  2017cites this paper
• A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicine

  2017influential citation
• A novel patient with an attenuated Costello syndrome phenotype due to an HRAS mutation affecting codon 146—Literature review and update

  2017cites this paper
• Aberrant HRAS transcript processing underlies a distinctive phenotype within the RASopathy clinical spectrum

  2017cites this paper
• The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions

  2016cites this paper
• Behavioral phenotype in Costello syndrome with atypical mutation: A case report

  2015cites this paper
• An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences

  2015influential citation
• A New Role for LOC101928437 in Non-Syndromic Intellectual Disability: Findings from a Family-Based Association Test

  2015cites this paper
• Behavioral Profile in RASopathies

  2014cites this paper
• Molecular Genetics of Costello Syndrome

  2014cites this paper
• Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation.

  2014cites this paper
• ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7

  2014cites this paper
• The role of p19 C-H-Ras protein in metastasis and proliferative pathways

  2013cites this paper
• Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.

  2013influential citation
• Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.

  2013influential citation
• A Mathematical Model of CR3/TLR2 Crosstalk in the Context of Francisella tularensis Infection

  2012cites this paper
• Biochemical assays to characterize Rho GTPases.

  2012cites this paper
• Transmission of the rare HRAS mutation (c. 173C > T; p.T58I) further illustrates its attenuated phenotype

  2012cites this paper
• Counteracting Effects Operating on Src Homology 2 Domain-containing Protein-tyrosine Phosphatase 2 (SHP2) Function Drive Selection of the Recurrent Y62D and Y63C Substitutions in Noonan Syndrome*♦

  2012cites this paper
• Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders

  2011cites this paper
• HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome

  2011cites this paper
• Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations

  2011cites this paper
• Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanisms

  2010cites this paper